LFA
REGN icon

LGT Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

LGT Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$1.05K – 591
2025
Q2 		$1.05K Buy
+2
New +$1.12K ﹤0.01% 390
2024
Q3 		– Sell
-6
Closed -$6.31K – 774
2024
Q2 		$6.31K Hold
6
– – 0.01% 556
2024
Q1 		$5.78K Hold
6
– – 0.01% 598
2023
Q4 		$5.27K Hold
6
– – 0.01% 620
2023
Q3 		$4.94K Buy
+6
New +$4.71K 0.01% 622

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LGT Financial Advisors's REGN Position: Q3 2025 in Review

LGT Financial Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 2 shares — an estimated $1.05K sold.

LGT Financial Advisors first reported a position in REGN in Q3 2023 and held it in 5 quarters. The position peaked at $6.31K in Q2 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • LGT Financial Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 2 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $1.05K.
  • LGT Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • LGT Financial Advisors's Regeneron Pharmaceuticals position peaked at $6.31K in Q2 2024.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on LGT Financial Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.